Table 1. Clinical and microbiological features of pulmonary infection with Mycobacterium triplexa.
| Characteristic | Patient described in reference 15 | Patient described in reference 16 | Our patient |
|---|---|---|---|
| Age/Sex | 67/F | 54/F | 54/F |
| Symptoms | Hemoptysis | Cough, hemoptysis, fever, fatigue | Cough, fatigue |
| Findings | Bronchiectases, lung nodules | Lung infiltrates and nodule (0.3 cm) | Bronchiectases, lung nodules, cavitations |
| Collected samples (no.) | Bronchial aspirate (1), sputum (3) | BAL (2), sputum (4) | Bronchial aspirate (7), BAL (2) |
| Smear-positive | None | None | 6 |
| Culture-positive | 3 | 3 | 9 |
| Mean no. CFU/mL (range) | NR | NR | 693 (144–2,772) |
| In vitro testing | |||
| S | RMP, SM, CLA | NR | CLA |
| I | CIP | NR | AN, CIP, EMB, ETH, RBT, SM |
| R | EMB, INH, PZA | NR | INH, RMP |
| Therapeutic schedule (mo.) | RMP, CIP, EMB, CLA (18) | RMP, INH, CLA (NR) | INH, RMP, EMB (6); EMB, CLA (9); LVX, CLA, EMB (9) |
| Outcome | Healed | NR | Slight improvement |
aBAL, bronchoalveolar lavage; NR, not reported; S, susceptible; I, moderately susceptible; R, resistant; RMP, rifampin; SM, streptomycin; CLA, clarithromycin; CIP, ciprofloxacin; AN, amikacin; EMB, ethambutol; ETH, ethionamide; RBT, rifabutin; INH, isoniazid; PZA, pyrazinamide; LVX, levofloxacin.